1. 1. Committee for Proprietary Medicinal Products (CPMP) . Points to consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. The European Agency for the Evaluation of Medicinal Products , 17, 1997 .
2. 2. Health Canada . Draft guidance "Assessment of the QT prolongation potential of non-antiarrhythmic drugs.", 2001 . Available athttp//www.hc-sh.gc.ca/hpb-dgps/therapeut/htmleng/guidmain.html.
3. 3. Food and Drug Administration and Health Canada . The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs . Preliminary Concept paper, 2002 . Available athttp//www.fda.gov/cder/workshop.htm#upcoming.
4. Arrhythmogenic mechanisms of non-sedating antihistamines
5. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers